<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858558</url>
  </required_header>
  <id_info>
    <org_study_id>J1343</org_study_id>
    <secondary_id>NA_00084466</secondary_id>
    <nct_id>NCT01858558</nct_id>
  </id_info>
  <brief_title>Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma</brief_title>
  <official_title>Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out if altering the immune system by giving Prevnar
      vaccine, Tadalafil, and activated marrow infiltrating lymphocytes (MILs) can improve outcomes
      for multiple myeloma patients who receive a standard autologous stem cell transplant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the efficacy of Activated Marrow Infiltrating Lymphocytes (MILs) in prolonging progression free survival (PFS) in patients with high risk multiple myeloma followed by Autologous Stem Cell Transplantation (ASCT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events related to the infusion of activated MILs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>aMIL Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No aMIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aMIL</intervention_name>
    <description>Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
    <arm_group_label>aMIL Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No aMIL</intervention_name>
    <description>Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.</description>
    <arm_group_label>aMIL Arm</arm_group_label>
    <arm_group_label>No aMIL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 80 years old;

          -  Patients with active myeloma requiring systemic treatment;

          -  Newly diagnosed patients. Relapsed myeloma patients that have not previously had a
             transplant;

          -  Meeting criteria for high-risk disease;

          -  Measurable serum and/or urine M-protein from prior to induction therapy documented and
             available. A positive serum free lite assay is acceptable;

          -  ECOG performance status of 0 - 2 (see Appendix C).

          -  Meet all institutional requirements for autologous stem cell transplantation;

          -  The patient must be able to comprehend and have signed the informed consent;

          -  Patients must have had &gt; than PR after last therapy.

        Exclusion Criteria:

          -  Diagnosis of any of the following cancers:

               -  POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,
                  endocrinopathy, monoclonal protein [M-protein] and skin changes);

               -  Non-secretory myeloma (no measurable protein on Serum Free Lite Assay);

               -  Plasma cell leukemia;

          -  Diagnosis of amyloidosis;

          -  Failed to achieve at least a partial response (PR) to latest therapy;

          -  Previous hematopoietic stem cell transplantation;Patients can have had prior relapsed
             disease as long as they have never been previously transplanted;

          -  Known history of HIV infection;

          -  Use of corticosteroids (glucocorticoids) within 21 days of bone marrow collection;

          -  Use of any myeloma-specific therapy within 21 days of bone marrow collection;

          -  Infection requiring treatment with antibiotics, antifungal, or antiviral agents within
             seven days of registration;

          -  Participation in any clinical trial within 28 days of registration on this trial,
             which involved an investigational drug or device;

          -  History of malignancy other than multiple myeloma within five years of registration,
             except adequately treated basal or squamous cell skin cancer;

          -  Active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic
             lupus erythematosis) requiring active systemic treatment. Hypothyroidism without
             evidence of Grave's disease or Hashimoto's thyroiditis is permitted.

          -  HTLV 1 or 2 positive;

          -  Known hypersensitivity to Prevnar or any of its components;

          -  Contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Borrello, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivan Borrello, M.D.</last_name>
    <phone>410-955-4967</phone>
    <email>iborrell@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Sidorski, Nurse Practitioner</last_name>
    <email>akramer3@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Borrello, M.D.</last_name>
      <phone>410-955-4967</phone>
    </contact>
    <investigator>
      <last_name>Ivan Borrello, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

